Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 4, 1998, Pages 763-767

  Raleigh, S M ^a   Wanogho, E ^a   Burke, M Danny ^a   McKeown, S R ^b   Patterson, L H ^a  

^a DE MONTFORT UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

AQ4N; Bioreduction; CYP 1A; CYP 2C; CYP 2D; CYP 3A; Hypoxia

Indexed keywords

ANTHRAQUINONE; ANTHRAQUINONE DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 3A; PRODRUG; RESORUFIN; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANAEROBIC METABOLISM; CONFERENCE PAPER; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; LIVER MICROSOME; MALE; PRIORITY JOURNAL; RADIOSENSITIVITY; SOLID TUMOR; TISSUE OXYGENATION;

ADULT; AGED; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION;

EID: 0031742538     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00308-3     Document Type: Conference Paper

References (34)

1. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen supply and metabolic microenvironment of human tumours A review . Cancer Res. 49:1989;6449-6465.
2. Brown J.M., Giaccia A.J. Tumour hypoxia The picture has changed in the 1990s . Int J Radiat Biol. 65:(1):1994;95-102.
3. Workman P., Stratford I.J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metast Rev. 12:1993;73-82.
4. Workman P., Walton M.I. Enzyme-directed bioreductive drug development. Adams G.E., Breccia A., Wardman P., Fielden E.M. Selective activation of drugs by redox processes. 1990;173-191 Plenum Press, New York.
5. Patterson L.H., Craven M.R., Fisher G.R., Teesdale-Spittle P. Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. Oncol Res. 6:1994;533-538.
6. Smith P.J., Blunt J.N., Desnoyers R., Giles Y., Patterson L.H. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Cancer Chemother Pharmacol. 39:1997;455-461.
7. Smith P.J., Desnoyers R., Blunt N., Giles Y., Patterson L.H., Watson J.V. Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation. Cytometry. 27:1997;43-53.
8. Cole S, Patterson LH, Williams CA, Bowler JD, Raleigh SM, Stratford IJ. The activity of AQ4N, a novel bioreductively-activated cytotoxin against KHT, RIF-1 and SCCVII murine tumours in vivo. 9th International Conference on Chemical Modifiers of Cancer Treatment. 1995 (Abstr).
9. McKeown S.R., Hejmadi M.V., McIntyre I.A., McAleer J.J.A., Patterson L. HAQ4N An alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo . Br J Cancer. 72:1995;76-81.
10. McKeown S.R., Friery O.P., McIntyre I.A., Hejmadi M.V., Patterson L.H., Hirst D.G. Evidence of therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br J Cancer. 74:(Suppl. 27):1996;S39-S42.
11. Wilson W.R., Denny W.A., Pullen S.M., Thompson K.M., Li A.E., Patterson L.H., Lee H.H. Tertiary amine N-oxides as bioreductive drugs DACA N-oxide, nitracrine N-oxide and AQ4N . Br J Cancer. 74:(Suppl. 27):1996;S43-S47.
12. Patterson L.H. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents A new class of bioreductive drugs . Cancer Metast Rev. 12:1993;119-134.
13. Weaver R.J., Thompson S., Smith G., Dickins M., Elcombe C.R., Mayer R.T., Burke M.D. A comparative study of constitutive and induced alkoxyresorufin O-dealkylation and individual cytochrome P450 forms in cynomolgus monkey (Macaca fascicularis), human, mouse, rat and hamster liver microsomes. Biochem Pharmacol. 47:1994;763-773.
14. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt Biochem. 72:1976;248-254.
15. Burke M.D., Thompson S., Elcombe C.R., Halpert J., Haaparanta T., Mayer R.T. Ethoxy, pentoxy and benzyloxy-phenoxazones and homologues A series of substrates to distinguish between different induced cytochromes P450 . Biochem Pharmacol. 34:1985;3337-3345.
16. Miners J.O., Smith K.J., Robson R.A., Mc Manus M.E., Veronese M.E., Birkett D.J. Tolbutamide hydroxylation by human liver microsomes. Biochem Pharmacol. 37:1986;1137-1144.
17. Jacolot F., Simon I., Dreano Y., Beaune P., Riche C., Berthou F. Identification of the cytochromes P450 IIIA family as the enzymes involved in the N-demethylation. Biochem Pharmacol. 1991;1911-1919.
18. Dayer P., Desmeules J., Leemann T., Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalysing debrisoquine 4-hydroxylation (cytochrome P450 dbl/bufI). Biochem Biophys Res Commun. 152:1988;411-416.
19. Burke M.D., Thompson S., Weaver R.J., Wolf C.R., Mayer R.T. Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol. 48:1994;923-936.
20. Crewe H.K., Ellis S.W., Lennard M.S., Tucker G.T. Variable contributions of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol. 53:1997;171-178.
21. Relling M.V., Aoyama T., Gonzalez F.J., Meyer U.A. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP 2C subfamily. J Pharm Exp Ther. 1990;442-447.
22. Boberg M., Angerbauer R., Fey P., Kanhai W.K., Karl W., Kern A., Ploschke J., Radbke M. Metabolism of cerivastatin by human liver microsomes in vitro characterization of primary metabolic pathways and of cytochrome P450 isozymes involved . Drug metabolism and disposition. 25:1997;321-331.
23. Chang T.K., Gonzalez F.J., Waxman D.J. Evaluation of triacetyloleandomycin, alpha-naphtoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys. 311:1994;437-442.
24. King L.H., Graham M.A., Workman P., Henderson C., Wolf C.R., Patterson L.H. Identification of cyt P450 2C8 as the major human P450 isoform involved in the bioreduction of the novel anthraquinone di-N-oxide, AQ4N. Br J Cancer. 67:(Suppl. 20):1993;9.
25. McKay J.A., Murray G.I., Weaver R.J., Ewen S.W.B., Melvin W.T., Burke M.D. Xenobiotic metabolising enzyme expression in colonic neoplasia. Gut. 34:1993;1234-1239.
26. De Waziers I., Cugnenc A., Berger A., Pleroux J., Beaune P.H. Drug metabolising enzyme expression in human normal, peritumoural and tumoural colorectal tissue samples. Carcinogenesis. 12:1991;905-909.
27. Murray G.I., McKay J.A., Weaver R.J., Ewen S.W.B., Melvin W.T., Burke M.D. Cytochrome P450 expression is a common molecular event in soft tissue sarcomas. J Pathol. 171:1993;49-52.
28. Murray G.I., Weaver R.J., Paterson P.J., Ewen S.W.B., Melvin W.T., Burke M.D. Expression of xenobiotic metabolising enzymes in breast cancer. J Pathol. 169:1993;347-353.
29. Chabot G.G., Verjus M.A., Mathieu M.C. Determination of cytochrome P450 isoenzymes of the 3A subfamily in human breast cancer. Proc Am Assoc Cancer Res. 38:1997;562. (Abstr).
30. Kivisto K.T., Fritz P., Linder A., Friedel G., Beaune P., Kroemer H.K. Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue. Histochemistry. 103:1995;25-29.
31. Murray G.I., Shaw D., Weaver R.J., Mc Kay J.A., Ewen S.W.B., Melvin W.T., Burke M.D. Cytochrome P450 expression in oesophageal cancer. Gut. 35:1994;599-603.
32. Fritz P., Behrle E., Beuane P., Eichelbaum M., Kromer H.K. Differential expression of drug metabolising enzymes in primary and secondary liver neoplasms Immunohistochemical characterisation of cytochrome P450 3A and glutathione S-transferase . Histochemistry. 99:1993;443-451.
33. Murray G.I., Taylor V.E., Mc Kay J.A., Weaver R.J., Ewen S.W.B., Melvin W.T., Burke M.D. Expression of xenobiotic metabolising enzymes in tumours of the urinary bladder. Int J Exp Pathol. 76:1995;271-276.
34. Murray G.I., Taylor V.E., Mc Kay J.A., Weaver R.J., Ewen S.W.B., Melvin W.T., Burke M.D. Immunochemical localisation of drug metabolising enzymes in prostate cancer. J Pathol. 177:1995;147-152.